InternationalUSRemember you can easily switch between MIP US and MIP International at any time

India: Novartis fights on in Gleevec battle


Novartis has now appealed to the Supreme Court in a bid to overturn the rejection of its controversial patent for Gleevec. Archana Shanker of Anand and Anand discusses the issues raised by the case

The speculation seemed to have come to an end on June 26 2009 when the Intellectual Property Appellate Board (IPAB) gave its decision on the Novartis patent application directed to the beta crystalline version of imatinib mesylate (Gleevec), refusing the...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

"The recent proposal of automatically granting pending applications without examination is nothing but a desperate… https://t.co/9lE4RD00Rz

Nov 20 2017 09:17 ·  reply ·  retweet ·  favourite
ManagingIP profile

New speakers announced at our NY https://t.co/sCxge69xRz and CA https://t.co/BGVnkVWSpC European Patent Events. F… https://t.co/3MlekFfPZR

Nov 20 2017 03:33 ·  reply ·  retweet ·  favourite
ManagingIP profile

India’s Supreme Court pushes for faster IPR suits https://t.co/G0vmxWOc5g Delhi High Court has been given until mid… https://t.co/W576LiUGCF

Nov 20 2017 10:05 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null null null

null null null

October 2017

Courts grapple with scope of patent protection

The Supreme Court’s decision in Actavis v Eli Lilly introduced a doctrine of equivalents and arguably also established a doctrine of prosecution history estoppel in the UK. We look at the law across Europe, and the impact the decision might have. Kingsley Egbuonu, Michael Loney and James Nurton set the scene



Most read articles

Supplements